Skip to main content

A prospective study of peripheral blood DNA methylation at RPTOR, MGRN1 and RAPSN and risk of breast cancer

This is a preview of subscription content, access via your institution.

References

  1. Tang Q, Holland-Letz T, Slynko A, Cuk K, Marme F, Schott S, Heil J, Qu B, Golatta M, Bewerunge-Hudler M, Sutter C, Surowy H, Wappenschmidt B, Schmutzler R, Hoth M, Bugert P, Bartram CR, Sohn C, Schneeweiss A, Yang R, Burwinkel B (2016) DNA methylation array analysis identifies breast cancer associated - RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA. Oncotarget. doi:10.18632/oncotarget.11640

    Google Scholar 

  2. Severi G, Southey MC, English, Jung CH, Lonie A, McLean C, Tsimiklis H, Hopper JL, Giles GG, Baglietto L (2014) Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res Treat 148:665–673. doi:10.1007/s10549-014-3209-y

    CAS  Article  PubMed  Google Scholar 

  3. Dugué PA, English DR, MacInnis RJ, Jung CH, Bassett JK, FitzGerald LM, Wong EM, Joo JE, Hopper JL, Southey MC, Giles GG, Milne RL (2016) Reliability of DNA methylation measures from dried blood spots and mononuclear cells using the HumanMethylation450 k BeadArray. Sci Rep. 6:30317. doi:10.1038/srep30317

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Melissa C. Southey was supported by National Health and Medical Research Council (Grant Nos.: APP1011618, APP1061177).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Melissa C. Southey.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dugué, PA., Milne, R.L. & Southey, M.C. A prospective study of peripheral blood DNA methylation at RPTOR, MGRN1 and RAPSN and risk of breast cancer. Breast Cancer Res Treat 161, 181–183 (2017). https://doi.org/10.1007/s10549-016-4032-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-016-4032-4

Keywords

  • Breast Cancer
  • Discovery Phase
  • Familial Breast Cancer Case
  • Illumina Infinium HumanMethylation
  • Melbourne Collaborative Cohort Study